*REGULUS THERAPEUTICS Q4 OPERATING EXPENSES USD 13.746 MILLION
*REGULUS THERAPEUTICS Q4 INCOME FROM OPERATIONS USD -13.746 MILLION
*REGULUS THERAPEUTICS Q4 BASIC EPS USD -0.2
*REGULUS THERAPEUTICS Q4 PRETAX PROFIT USD -12.791 MILLION
*REGULUS THERAPEUTICS Q4 NET INCOME USD -12.791 MILLION
*REGULUS THERAPEUTICS: CO EXPECTS ITS CASH RUNWAY TO EXTEND INTO EARLY 2026
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 13-MAR-202520:05:03.45 GMT